N-(3-吡啶甲基)脲 | 36226-32-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: N-(3-吡啶甲基)脲
• 英文名称: 1-(pyridin-3-ylmethyl)urea
• 英文别名: Urea, (3-pyridinylmethyl)-；pyridin-3-ylmethylurea
• CAS: 36226-32-1
• 化学式: C₇H₉N₃O
• mdl: MFCD00134234
• 分子量: 151.168
• InChiKey: PWHUPFOHNXWYSH-UHFFFAOYSA-N

物化性质

• 熔点：
  181-183 °C(lit.)
• 沸点：
  321.3±34.0 °C(Predicted)
• 密度：
  1.208±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  68
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  三氟丙酮酸甲酯 、 N-(3-吡啶甲基)脲 以 乙腈 为溶剂， 反应 3.0h， 以73%的产率得到5-hydroxy-3-(pyridin-3-yl)methyl-5-trifluoromethylimidazolidine-2,4-dione
  参考文献：
  名称：

  Methyl Trifluoropyruvate in Cyclocondensation Reactions with N-Substituted Ureas

  摘要：

  The transformations of methyl trifluoropyruvate in cyclocondensation reactions with N-substituted ureas, leading to 3-substituted 5-hydroxy- or 5-methoxy-5-trifluoromethylimidazolidine-2,4-diones, were studied. The possibility of using 5-hydroxy-3-(prop-2-in-1-yl)-5-trifluoromethylimidazolidine-2,4-dione for modifying phenothiazine with a copper-catalyzed alkyne-azide 1,3-dipolar cycloaddition was shown.

  DOI：

  10.1134/s1070363219010286
• 作为产物：
  描述：

  phenyl (pyridin-3-ylmethyl)carbamate 在 ammonium hydroxide 作用下， 以 乙醇 为溶剂， 反应 4.0h， 以92%的产率得到N-(3-吡啶甲基)脲
  参考文献：
  名称：

  [EN] DIAZABICYCLOOCTANE DERIVATIVES COMPRISING A QUATERNERY AMMONIUM GROUP FOR USE AS ANTIBACTERIAL AGENTS
  [FR] DÉRIVÉS DE DIAZABICYCLOOCTANE COMPRENANT UN GROUPE D'AMMONIUM QUATERNAIRE DESTINÉ À ÊTRE UTILISÉ EN TANT QU'AGENTS ANTIBACTÉRIENS

  摘要：

  公开了化合物（I）的化合物，包括这些化合物的药物组合物以及它们在治疗细菌感染中的用途。

  公开号：

  WO2018203194A1

文献信息

• [EN] PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE<br/>[FR] DÉRIVÉS DE PYRIDINYLE UTILISÉS EN TANT QU'INHIBITEURS DE L'ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFÉRASE
  申请人：TOPOTARGET AS

  公开号：WO2010142735A1

  公开（公告）日：2010-12-16

  The present application discloses a compound of the formula (I) wherein Q is optionally substituted pyridyl; p is 0-6; Y is formulae (i), (ii) and (iii) where X is =O, =S and =N-CN, r is 1-12, R is -Z-A, Z is a single bond, -S(=O)2-, >P=O, >C=O, -C(=O)NH-, and -C(=S)NH-; and A is hydrogen, C1-12-alkyl, C3-12-cycloalkyl, - [CH2CH2O]1-10-(C1-6-alkyl), C1-12-alkenyl, aryl, heterocyclyl, and heteroaryl; B is a single bond, -NRN-, -S(=O)2- and -O-; wherein RN is selected from hydrogen, C1-12-alkyl, C3-12-cycloalkyl, -[CH2CH2O]1-10-(C1-6-alkyl), C1-12-alkenyl, aryl, heterocyclyl, and heteroaryl; s is 0-6; and Cy is aryl, cycloalkyl, heterocyclyl, and heteroaryl. The compounds are usefuld for use as a medicament for the treatment of a disease or a condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT).

  本申请公开了一种化合物，其化学式为（I），其中Q是可选择取代的吡啶基；p为0-6；Y是式（i）、（ii）和（iii），其中X为=O、=S和=N-CN，r为1-12，R为-Z-A，Z为单键，-S(=O)2-，>P=O，>C=O，-C(=O)NH-和-C(=S)NH-；A为氢、C1-12-烷基、C3-12-环烷基、-[CH2CH2O]1-10-(C1-6-烷基)、C1-12-烯基、芳基、杂环烷基和杂芳基；B为单键，-NRN-，-S(=O)2-和-O-；其中RN从氢、C1-12-烷基、C3-12-环烷基、-[CH2CH2O]1-10-(C1-6-烷基)、C1-12-烯基、芳基、杂环烷基和杂芳基中选择；s为0-6；Cy为芳基、环烷基、杂环烷基和杂芳基。这些化合物可用作治疗由烟酰胺磷酸核糖转移酶（NAMPRT）水平升高引起的疾病或症状的药物。
• [EN] INDAZOLOPYRIMIDINONES AS FIBRINOLYSIS INHIBITORS<br/>[FR] INDAZOLOPYRIMIDINONES COMME INHIBITEURS DE LA FIBRINOLYSE
  申请人：BAYER PHARMA AG

  公开号：WO2016173948A1

  公开（公告）日：2016-11-03

  The present application relates to novel substituted indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

  本申请涉及新型取代吲唑吡咯嘧啶酮，其制备方法，以及用于治疗和/或预防疾病的化合物，特别是用于治疗和/或预防患有或不患有基础遗传或获得性止血障碍的患者急性和复发性出血的方法，其中出血与从重经期出血、产后出血、出血性休克、创伤、手术、移植、中风、肝病、遗传性血管性水肿、鼻血、以及血液积聚后的滑膜炎和软骨损伤等一组疾病或医疗干预有关。
• [EN] PYRIMIDINE FGFR4 INHIBITORS<br/>[FR] INHIBITEURS DE FGFR4 PYRIMIDINE
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2015057938A1

  公开（公告）日：2015-04-23

  Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.

  本文提供了作为FGFR4抑制剂有用的I式化合物，以及其使用方法。
• Modification of biologically active amides and amines with fluorine-containing heterocycles 12.* Endo- and exocyclic modifications of the drug riluzole with trifluoromethyl-containing heterocycles
  作者：V. B. Sokolov、A. Yu. Aksinenko、A. V. Sokolov、A. Gabrelian、A. D. Efimova、V. V. Grigoriev

  DOI：10.1007/s11172-017-1706-y

  日期：2017.1

  New derivatives of the drug riluzole, 6-(trifluoromethoxy)benzothiazol-2-ylamine, modified at the endo- and exocyclic nitrogen atoms with trifluoromethyl-containing heterocycles were synthesized via transformations of methyltrifluoropyruvate and hexafluoroacetone N-6-(trifluoromethoxy)benzothiazol-2-ylimines by meams of cycloaddition and cyclocondensation reactions, respectively. The influence of the

  通过甲基三氟丙酮酸和六氟丙酮 N-6-(三氟甲氧基)苯并噻唑-2的转化，合成了药物利鲁唑的新衍生物，6-(三氟甲氧基)苯并噻唑-2-基胺，在环内和环外氮原子上用含三氟甲基的杂环修饰-ylimines 分别通过环加成和环缩合反应。研究了所得化合物对神经元 NMDA 受体以及神经递质谷氨酸盐的释放和再摄取的影响。
• [EN] SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRROLOPYRIDINE SUBSTITUÉS
  申请人：BAYER PHARMA AG

  公开号：WO2018228920A1

  公开（公告）日：2018-12-20

  The present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives of formula (I) in which X, Y, R1, R2, R3 and R4 are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, repectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.

  本发明涉及公式（I）中X、Y、R1、R2、R3和R4如本文所定义的蛋白抑制取代吡咯吡啶衍生物，涉及包含根据本发明的化合物的药物组合物和制剂，以及创新化合物的预防和治疗用途，分别用于制造用于治疗或预防疾病的药物组合物，特别是用于恶性肿瘤障碍，癌症或与MAP4K1信号异常相关的其他疾病，作为唯一药剂或与其他活性成分组合使用。本发明还涉及用途，分别用于制造药物组合物，用于治疗或预防良性增生中的蛋白酶抑制剂，在动脉粥样硬化疾病、败血症、自身免疫疾病、血管疾病、病毒感染、神经退行性疾病、炎症性疾病、动脉粥样硬化疾病和男性生育控制方面。